Format

Send to

Choose Destination
Pancreas. 2018 Nov/Dec;47(10):1185-1192. doi: 10.1097/MPA.0000000000001175.

Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis: Summary of the Working Group on Drug Development and Trials in Acute Pancreatitis at the National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Author information

1
Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
2
Department of Medicine, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Darmouth University, Hanover, NH.
3
Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
4
Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL.
5
Division of Gastroenterology, Department of Medicine, University of John's Hopkins, Baltimore, MD.
6
Stead Family Department of Pediatrics, University of Iowa, Stead Family Children's Hospital, Iowa City, IA.
7
Center for Pancreatic Care, Department of Gastroenterology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA.

Abstract

A workshop was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases to focus on research gaps and opportunities on drug development for pancreatitis. This conference was held on July 25, 2018, and structured into 3 working groups (WG): acute pancreatitis (AP) WG, recurrent AP WG, and chronic pancreatitis WG. This article reports the outcome of the work accomplished by the AP WG to provide the natural history, epidemiology, and current management of AP; inform about the role of preclinical models in therapy selection; and discuss clinical trial designs with clinical and patient-reported outcomes to test new therapies.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center